Market Overview

Afternoon Market Gainers

Related BLUE
Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks
Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Estimates
Related NKTR
Baxalta Announces FDA Approval of ADYNOVATE Treatment for Hemophilia A
Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies

Bluebird Bio (NASDAQ: BLUE) traded up 49.55 percent to $25.41. Wednesday's IPO for the company was initially priced at $17.

Nektar Therapeutics (NASDAQ: NKTR) rose 9.99 percent to $10.79 after announcing positive top-line results from a human abuse liability (HAL) study for NKTR-181.

Gevo (NASDAQ: GEVO) climbed 9.23 percent to $2.26 after yesterday's announcement that it had resumed commercial production of Isobutanol.

Keryx BioPharma (NASDAQ: KERX) shot up 6.50 percent to $8.16 after analysts at JP Morgan initiated coverage on the stock with an Overweight rating.

MannKind (NASDAQ: MNKD) regained 6.48 percent to $7.03 after yesterday's double-digit drop.

Posted-In: News Movers


Related Articles (GEVO + BLUE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters